Additionally, a xenograft tumor mouse model was established to validate the data about the repression of METTL14 knockdown on NPC cell malignancy in vivo. Results showed that the volumes and weights of in situ tumors dropped in response to METTL14 downregulation relative to those of the sh-NC control group (Fig. 8A and 8B), suggesting the inhibitory role of METTL14 deficiency on NPC tumor growth. Here, METTL14 is linked to nasopharyngeal carcinoma.